眼内注射组织型纤溶酶原激活物对视网膜静脉阻塞继发黄斑水肿患者全视野视网膜电图的影响。
Impact of intravitreal injection of tissue plasminogen activator on full-field electroretinogram in patients with macular oedema secondary to retinal vein occlusion.
机构信息
Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
出版信息
Ophthalmologica. 2011;226(2):81-6. doi: 10.1159/000326242. Epub 2011 May 31.
PURPOSE
To evaluate the retinal toxicity of intravitreal tissue plasminogen activator (tPA) injection for branch and central retinal vein occlusion (BRVO and CRVO) using the electroretinogram (ERG).
PROCEDURES
Ten BRVO patients and 5 CRVO patients were enrolled. A complete examination including full-field ERG, visual acuity, central retinal thickness (CRT), and evaluation of systemic and ocular complications was performed before and after intravitreal tPA injection.
RESULTS
No significant differences were found in the amplitude or implicit time of any ERG component after tPA injection, and no systemic or ocular complication was observed. The improvement of visual acuity was significant at month 3 in the BRVO group (p < 0.05) but not in the CRVO group. CRT significantly decreased over the course of 3 months in both groups (p < 0.01).
CONCLUSION
Intravitreal tPA injection seems to be a safe and effective treatment option for macular oedema caused by retinal vein occlusions.
目的
通过视网膜电图（ERG）评估玻璃体内组织型纤溶酶原激活物（tPA）注射治疗视网膜分支静脉阻塞（BRVO）和视网膜中央静脉阻塞（CRVO）的视网膜毒性。
方法
纳入 10 例 BRVO 患者和 5 例 CRVO 患者。在玻璃体内 tPA 注射前后进行了包括全视野 ERG、视力、中心视网膜厚度（CRT）以及全身和眼部并发症评估在内的完整检查。
结果
tPA 注射后 ERG 各成分的振幅或潜伏期均无显著差异，未观察到全身或眼部并发症。BRVO 组视力在 3 个月时显著改善（p<0.05），但 CRVO 组无此变化。两组 CRT 在 3 个月内均显著下降（p<0.01）。
结论
玻璃体内 tPA 注射似乎是治疗视网膜静脉阻塞引起的黄斑水肿的一种安全有效的治疗选择。
Zotero 插件